bepridil has been researched along with Auricular Fibrillation in 51 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 9.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan." | 9.16 | The relationship between the plasma concentration of bepridil and its efficacy in the treatment of atrial fibrillation in Japanese patients. ( Gotoh, Y; Iwai, S; Katoh, N; Kobayashi, M; Narayama, Y; Noda, K; Tadano, K; Tanioka, S, 2012) |
| "A multicenter, randomized, placebo-controlled, double-blind trial was conducted with patients with persistent atrial fibrillation (AF) to determine the dose-response effects and safety of bepridil, using every-day transtelephonic monitorings." | 9.14 | Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study). ( Aizawa, Y; Atarashi, H; Fujiki, A; Inoue, H; Ito, M; Katoh, T; Kobayashi, Y; Koretsune, Y; Kumagai, K; Niwano, S; Ogawa, S; Okazaki, O; Okumura, K; Origasa, H; Saku, K; Sato, T; Tanabe, T; Yamashita, T, 2009) |
| "This study has evaluated whether candesartans prevent the recurrence of atrial fibrillation (AF) and decrease type III procollagen-N-peptide (PIIINP) levels." | 9.14 | Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Miyoshi, F; Onuki, T; Tanno, K; Watanabe, N, 2010) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 9.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 9.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 9.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "The aim of this study was to evaluate pharmacological cardioversion of long-lasting persistent atrial fibrillation (AF) using bepridil in terms of recovery of atrial mechanical function and maintenance of sinus rhythm." | 9.11 | Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. ( Fujiki, A; Hirai, T; Inoue, H; Mizumaki, K; Nakagawa, K; Sakabe, M; Tsuneda, T, 2004) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 9.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "The aim of this study was to investigate the efficacy and safety of bepridil (a multichannel blocker including several potassium channels) for conversion of long-lasting atrial fibrillation (AF)." | 9.10 | Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. ( Fujiki, A; Inoue, H; Mizumaki, K; Sugao, M; Tsuneda, T, 2003) |
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 8.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| "Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF)." | 7.78 | Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation. ( Chishaki, A; Chishaki, H; Inoue, S; Mukai, Y; Shamoto, A; Sunagawa, K; Takemoto, M; Tsuchihashi-Makaya, M, 2012) |
| "Although bepridil is effective for conversion of long-lasting persistent atrial fibrillation (AF) to sinus rhythm, it sometimes takes a long time to interrupt AF and there is no feasible index to predict its efficacy." | 7.77 | Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation. ( Aoyama, Y; Fukumoto, K; Ishikawa, S; Izumi, T; Kishihara, J; Murakami, M; Niwano, H; Niwano, S; Satoh, A; Ueno, K, 2011) |
| "It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil." | 7.77 | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. ( Hagiwara, N; Hosaka, F; Naganuma, M; Shiga, T; Shoda, M; Suzuki, A, 2011) |
| "Because bepridil blocks multiple myocardial ionic channels, including the muscarinic acetylcholine receptor-operated potassium current (I(KAch)), bepridil is expected to suppress atrial fibrillation (AF) mediated by vagal nerve stimulation (VNS)." | 7.76 | Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. - Prevention of vagal nerve activation-induced shortening of the atrial action potential duration -. ( Ahara, S; Aizawa, Y; Chinushi, M; Furushima, H; Hosaka, Y; Iijima, K; Izumi, D; Komura, S; Sanada, A; Sato, A, 2010) |
| "Bepridil is highly effective in terminating persistent atrial fibrillation (AF)." | 7.75 | Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation. ( Isobe, M; Kobori, A; Kuwahara, T; Miyazaki, S; Sato, A; Takahashi, A; Takahashi, Y; Takei, A, 2009) |
| "Bepridil was administered to 125 consecutive patients with paroxysmal and persistent atrial fibrillations." | 7.74 | Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Minoura, Y; Miyoshi, F; Onuki, T; Tanno, K, 2007) |
| "Two patients presented with atrial fibrillation which was refractory to amiodarone but successfully treated with bepridil." | 7.73 | [Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports]. ( Hadano, Y; Iwami, T; Kimura, M; Matsuzaki, M; Miyazaki, Y; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2006) |
| "Bepridil has multiple ion-channel blocking effects similar to amiodarone and is expected to have anti-arrhythmic effects that are useful for the management of atrial fibrillation (AF)." | 7.73 | Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. ( Daida, H; Iida, Y; Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Sumiyoshi, M; Tokano, T; Yasuda, M, 2005) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 7.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 7.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| " Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 6.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| "Bepridil was superior to amiodarone in achieving sinus conversion and in maintaining sinus rhythm after cardioversion in patients with persistent AF." | 6.77 | Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial. ( Daida, H; Nakazato, Y; Yamase, M, 2012) |
| "Bepridil alone or in combination with aprindine converted long lasting persistent AF in association with an increase in both FCL and FOI." | 6.71 | Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine. ( Fujiki, A; Inoue, H; Iwamoto, J; Mizumaki, K; Nishida, K; Sakabe, M; Sugao, M; Tsuneda, T, 2004) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 5.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 5.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan." | 5.16 | The relationship between the plasma concentration of bepridil and its efficacy in the treatment of atrial fibrillation in Japanese patients. ( Gotoh, Y; Iwai, S; Katoh, N; Kobayashi, M; Narayama, Y; Noda, K; Tadano, K; Tanioka, S, 2012) |
| "A multicenter, randomized, placebo-controlled, double-blind trial was conducted with patients with persistent atrial fibrillation (AF) to determine the dose-response effects and safety of bepridil, using every-day transtelephonic monitorings." | 5.14 | Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study). ( Aizawa, Y; Atarashi, H; Fujiki, A; Inoue, H; Ito, M; Katoh, T; Kobayashi, Y; Koretsune, Y; Kumagai, K; Niwano, S; Ogawa, S; Okazaki, O; Okumura, K; Origasa, H; Saku, K; Sato, T; Tanabe, T; Yamashita, T, 2009) |
| "This study has evaluated whether candesartans prevent the recurrence of atrial fibrillation (AF) and decrease type III procollagen-N-peptide (PIIINP) levels." | 5.14 | Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Miyoshi, F; Onuki, T; Tanno, K; Watanabe, N, 2010) |
| "Although bepridil is a useful anti-arrhythmic agent for atrial fibrillation, the appearance of serious ventricular arrhythmia, such as torsades de pointes, might be a problem." | 5.14 | Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event. ( Ishikawa, S; Izumi, T; Kiryu, M; Kosukegawa, T; Kurokawa, S; Moriguchi, M; Murakami, M; Niwano, H; Niwano, S; Yumoto, Y, 2010) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 5.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 5.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 5.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "The aim of this study was to evaluate pharmacological cardioversion of long-lasting persistent atrial fibrillation (AF) using bepridil in terms of recovery of atrial mechanical function and maintenance of sinus rhythm." | 5.11 | Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. ( Fujiki, A; Hirai, T; Inoue, H; Mizumaki, K; Nakagawa, K; Sakabe, M; Tsuneda, T, 2004) |
| "The aim of this study was to investigate the efficacy and safety of bepridil (a multichannel blocker including several potassium channels) for conversion of long-lasting atrial fibrillation (AF)." | 5.10 | Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. ( Fujiki, A; Inoue, H; Mizumaki, K; Sugao, M; Tsuneda, T, 2003) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 5.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 4.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| "Bepridil in combination with aprindine could restore sinus rhythm in patients with persistent atrial fibrillation (AF)." | 3.81 | Bepridil enhances aprindine-induced prolongation of atrial effective refractory period in a canine atrial rapid pacing model. ( Fujiki, A; Inoue, H; Kataoka, N; Mizumaki, K; Nakatani, Y; Nishida, K; Sakabe, M; Sakamoto, T; Yamaguchi, Y, 2015) |
| "Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF)." | 3.78 | Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation. ( Chishaki, A; Chishaki, H; Inoue, S; Mukai, Y; Shamoto, A; Sunagawa, K; Takemoto, M; Tsuchihashi-Makaya, M, 2012) |
| "Although bepridil is effective for conversion of long-lasting persistent atrial fibrillation (AF) to sinus rhythm, it sometimes takes a long time to interrupt AF and there is no feasible index to predict its efficacy." | 3.77 | Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation. ( Aoyama, Y; Fukumoto, K; Ishikawa, S; Izumi, T; Kishihara, J; Murakami, M; Niwano, H; Niwano, S; Satoh, A; Ueno, K, 2011) |
| "It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil." | 3.77 | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. ( Hagiwara, N; Hosaka, F; Naganuma, M; Shiga, T; Shoda, M; Suzuki, A, 2011) |
| "Because bepridil blocks multiple myocardial ionic channels, including the muscarinic acetylcholine receptor-operated potassium current (I(KAch)), bepridil is expected to suppress atrial fibrillation (AF) mediated by vagal nerve stimulation (VNS)." | 3.76 | Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. - Prevention of vagal nerve activation-induced shortening of the atrial action potential duration -. ( Ahara, S; Aizawa, Y; Chinushi, M; Furushima, H; Hosaka, Y; Iijima, K; Izumi, D; Komura, S; Sanada, A; Sato, A, 2010) |
| "Bepridil is highly effective in terminating persistent atrial fibrillation (AF)." | 3.75 | Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation. ( Isobe, M; Kobori, A; Kuwahara, T; Miyazaki, S; Sato, A; Takahashi, A; Takahashi, Y; Takei, A, 2009) |
| "Bepridil is highly effective in the treatment of atrial fibrillation, but its clinical usefulness is limited by a potential risk for the drug-induced Torsades de pointes (TdP) in association with its Class III action." | 3.75 | Opposing effects of bepridil on ventricular repolarization in humans. Inhomogeneous prolongation of the action potential duration vs flattening of its restitution kinetics. ( Hasebe, H; Kodama, I; Kuroda, Y; Kushiyama, Y; Osaka, T; Suzuki, T; Yokoyama, E, 2009) |
| "Bepridil was administered to 125 consecutive patients with paroxysmal and persistent atrial fibrillations." | 3.74 | Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Minoura, Y; Miyoshi, F; Onuki, T; Tanno, K, 2007) |
| "A 66-year-old man had been given bepridil for the treatment of atrial fibrillation since April 28, 2002." | 3.73 | [A case of drug-induced pneumonitis due to bepridil]. ( Ando, M; Ashihara, Y; Fukami, T; Ito, T; Kumamoto, T; Matsuno, O; Miyazaki, E; Nishitake, T; Okubo, F; Okubo, T, 2006) |
| "Bepridil has multiple ion-channel blocking effects similar to amiodarone and is expected to have anti-arrhythmic effects that are useful for the management of atrial fibrillation (AF)." | 3.73 | Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. ( Daida, H; Iida, Y; Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Sumiyoshi, M; Tokano, T; Yasuda, M, 2005) |
| "Two patients presented with atrial fibrillation which was refractory to amiodarone but successfully treated with bepridil." | 3.73 | [Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports]. ( Hadano, Y; Iwami, T; Kimura, M; Matsuzaki, M; Miyazaki, Y; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2006) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 3.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 3.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| " Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 2.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| "Bepridil was superior to amiodarone in achieving sinus conversion and in maintaining sinus rhythm after cardioversion in patients with persistent AF." | 2.77 | Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial. ( Daida, H; Nakazato, Y; Yamase, M, 2012) |
| "Pilsicainide and bepridil were effective in 19 and 20 patients, respectively." | 2.74 | Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG. ( Fujiki, A; Fukaya, H; Hatakeyama, Y; Izumi, T; Kiryu, M; Kurokawa, S; Niwano, H; Niwano, S; Sasaki, T, 2009) |
| "Bepridil alone or in combination with aprindine converted long lasting persistent AF in association with an increase in both FCL and FOI." | 2.71 | Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine. ( Fujiki, A; Inoue, H; Iwamoto, J; Mizumaki, K; Nishida, K; Sakabe, M; Sugao, M; Tsuneda, T, 2004) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "AT-type recurrence was observed in 16 patients (2 [3." | 1.62 | Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation. ( Doi, M; Hara, S; Ito, H; Morimoto, T; Morita, H; Okawa, K; Ozaki, M; Sogo, M; Sudo, Y; Takahashi, M; Tsushima, R, 2021) |
| "In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits." | 1.43 | Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. ( Chiba, T; Kondo, N; Takahara, A, 2016) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 1.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| " These samples were collected just before each dosage of bepridil." | 1.37 | An LC method for quantifying bepridil in human plasma using 1-naphthol as the internal standard. ( Goto, Y; Itoh, K; Iwai, S; Katoh, N; Kobayashi, M; Kuronuma, H; Narayama, Y; Noda, K; Tadano, K, 2011) |
| " In this study, the effect of long-term administration of bepridil on atrial electrical remodeling was evaluated in a comparison of the right and left atrium (RA and LA) in a canine rapid atrial stimulation model." | 1.35 | Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. ( Fukaya, H; Izumi, T; Kojima, J; Masaki, Y; Moriguchi, M; Niwano, H; Niwano, S; Satoh, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (52.94) | 29.6817 |
| 2010's | 19 (37.25) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Kazatani, T | 1 |
| Higaki, A | 1 |
| Tanaka, Y | 1 |
| Kawada, Y | 1 |
| Komatsu, Y | 1 |
| Yodoshi, M | 1 |
| Takegami, M | 1 |
| Yokoyama, S | 1 |
| Hosomi, K | 1 |
| Yakabe, D | 1 |
| Aso, A | 1 |
| Araki, M | 1 |
| Murasato, Y | 1 |
| Nakamura, T | 1 |
| Okawa, K | 1 |
| Hara, S | 1 |
| Morimoto, T | 1 |
| Tsushima, R | 1 |
| Sudo, Y | 1 |
| Sogo, M | 1 |
| Ozaki, M | 1 |
| Takahashi, M | 1 |
| Doi, M | 1 |
| Morita, H | 1 |
| Ito, H | 3 |
| Nishino, M | 1 |
| Mori, N | 1 |
| Nakamura, D | 1 |
| Lee, Y | 1 |
| Yoshimura, T | 1 |
| Taniike, M | 1 |
| Makino, N | 1 |
| Kato, H | 1 |
| Egami, Y | 1 |
| Shutta, R | 1 |
| Tanouchi, J | 1 |
| Yamada, Y | 1 |
| Shiga, T | 2 |
| Hashiguchi, M | 1 |
| Naganuma, M | 2 |
| Suzuki, A | 2 |
| Hagiwara, N | 2 |
| Nakatani, Y | 1 |
| Sakamoto, T | 3 |
| Nishida, K | 4 |
| Kataoka, N | 1 |
| Yamaguchi, Y | 1 |
| Sakabe, M | 3 |
| Fujiki, A | 9 |
| Mizumaki, K | 6 |
| Inoue, H | 7 |
| Kondo, T | 1 |
| Miake, J | 1 |
| Kato, M | 1 |
| Ogura, K | 1 |
| Iitsuka, K | 1 |
| Yamamoto, K | 1 |
| Chiba, T | 1 |
| Kondo, N | 1 |
| Takahara, A | 1 |
| Watanabe, M | 1 |
| Takata, Y | 1 |
| Fukasawa, S | 1 |
| Sakota, K | 1 |
| Abe, T | 1 |
| Goseki, Y | 1 |
| Setoguchi, Y | 1 |
| Chikamori, T | 1 |
| Yamashina, A | 1 |
| Yamashita, T | 2 |
| Ogawa, S | 1 |
| Sato, T | 1 |
| Aizawa, Y | 2 |
| Atarashi, H | 1 |
| Ito, M | 1 |
| Katoh, T | 1 |
| Kobayashi, Y | 4 |
| Koretsune, Y | 1 |
| Kumagai, K | 1 |
| Niwano, S | 8 |
| Okazaki, O | 1 |
| Okumura, K | 1 |
| Saku, K | 1 |
| Tanabe, T | 1 |
| Origasa, H | 1 |
| Sasaki, T | 1 |
| Kurokawa, S | 2 |
| Kiryu, M | 3 |
| Fukaya, H | 3 |
| Hatakeyama, Y | 1 |
| Niwano, H | 5 |
| Izumi, T | 7 |
| Hirao, K | 1 |
| Osaka, T | 1 |
| Yokoyama, E | 1 |
| Kushiyama, Y | 1 |
| Hasebe, H | 1 |
| Kuroda, Y | 1 |
| Suzuki, T | 1 |
| Kodama, I | 1 |
| Miyazaki, S | 1 |
| Kuwahara, T | 1 |
| Kobori, A | 1 |
| Takahashi, Y | 1 |
| Takei, A | 1 |
| Sato, A | 2 |
| Isobe, M | 1 |
| Takahashi, A | 1 |
| Nakaya, H | 1 |
| Kawamura, M | 3 |
| Onuki, T | 2 |
| Miyoshi, F | 2 |
| Watanabe, N | 1 |
| Asano, T | 2 |
| Tanno, K | 3 |
| Murakami, M | 2 |
| Ishikawa, S | 2 |
| Yumoto, Y | 1 |
| Moriguchi, M | 3 |
| Kosukegawa, T | 1 |
| Iijima, K | 1 |
| Chinushi, M | 1 |
| Izumi, D | 1 |
| Ahara, S | 1 |
| Furushima, H | 1 |
| Komura, S | 1 |
| Hosaka, Y | 1 |
| Sanada, A | 1 |
| Masaki, Y | 2 |
| Hirasawa, S | 1 |
| Sato, D | 1 |
| Hosaka, F | 1 |
| Shoda, M | 1 |
| Noda, K | 2 |
| Narayama, Y | 2 |
| Goto, Y | 1 |
| Kobayashi, M | 2 |
| Kuronuma, H | 1 |
| Iwai, S | 2 |
| Itoh, K | 1 |
| Katoh, N | 2 |
| Tadano, K | 2 |
| Aoyama, Y | 1 |
| Satoh, A | 1 |
| Kishihara, J | 1 |
| Fukumoto, K | 1 |
| Ueno, K | 1 |
| Gotoh, Y | 1 |
| Tanioka, S | 1 |
| Yamase, M | 1 |
| Nakazato, Y | 3 |
| Daida, H | 3 |
| Shamoto, A | 1 |
| Chishaki, A | 1 |
| Tsuchihashi-Makaya, M | 1 |
| Chishaki, H | 1 |
| Takemoto, M | 1 |
| Mukai, Y | 1 |
| Inoue, S | 1 |
| Sunagawa, K | 1 |
| Munetsugu, Y | 1 |
| Kunii, Y | 1 |
| Uruno, T | 1 |
| Matsumoto, M | 1 |
| Mukasa, K | 1 |
| Noh, J | 1 |
| Ito, K | 1 |
| Akaishi, M | 1 |
| Hori, S | 1 |
| Nakazawa, H | 1 |
| Yoshiga, Y | 1 |
| Shimizu, A | 2 |
| Yamagata, T | 1 |
| Hayano, T | 1 |
| Ueyama, T | 1 |
| Ohmura, M | 1 |
| Itagaki, K | 1 |
| Kimura, M | 2 |
| Matsuzaki, M | 2 |
| Yoshida, T | 2 |
| Inuo, K | 2 |
| Saito, J | 2 |
| Kojima, J | 3 |
| Ikeda-Murakami, K | 2 |
| Hara, H | 2 |
| Tsuneda, T | 3 |
| Sugao, M | 2 |
| Gaku, S | 1 |
| Naoshi, K | 1 |
| Teruhiko, A | 1 |
| Bollmann, A | 1 |
| Husser, D | 1 |
| Olsson, SB | 1 |
| Nakagawa, K | 1 |
| Hirai, T | 1 |
| Iwamoto, J | 2 |
| Yasuda, M | 2 |
| Sasaki, A | 2 |
| Iida, Y | 1 |
| Kawano, Y | 2 |
| Nakazato, K | 2 |
| Tokano, T | 2 |
| Mineda, Y | 1 |
| Sumiyoshi, M | 1 |
| Nakata, Y | 1 |
| Okumura, Y | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Sugimura, H | 1 |
| Hashimoto, K | 1 |
| Masaki, R | 1 |
| Ohkubo, K | 1 |
| Takagi, Y | 1 |
| Shindo, A | 1 |
| Ozawa, Y | 1 |
| Saito, S | 1 |
| Kanmatsuse, K | 1 |
| Okubo, F | 1 |
| Ando, M | 1 |
| Ashihara, Y | 1 |
| Okubo, T | 1 |
| Nishitake, T | 1 |
| Ito, T | 1 |
| Matsuno, O | 1 |
| Fukami, T | 1 |
| Miyazaki, E | 1 |
| Kumamoto, T | 1 |
| Sugi, K | 1 |
| Nagasawa, H | 1 |
| Ogawa, H | 1 |
| Wakeyama, T | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Hadano, Y | 1 |
| Miyazaki, Y | 1 |
| Miyaji, K | 1 |
| Tada, H | 1 |
| Fukushima Kusano, K | 1 |
| Hashimoto, T | 1 |
| Kaseno, K | 1 |
| Hiramatsu, S | 1 |
| Tadokoro, K | 1 |
| Naito, S | 1 |
| Nakamura, K | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Ohe, T | 1 |
| Minoura, Y | 1 |
| Satoh, D | 1 |
| Imai, S | 1 |
| Saito, F | 1 |
| Takase, H | 1 |
| Enomoto, M | 1 |
| Aoyama, H | 1 |
| Yamaji, S | 1 |
| Yokoyama, K | 1 |
| Yagi, H | 1 |
| Kushiro, T | 1 |
| Hirayama, A | 1 |
| Perelman, MS | 1 |
| McKenna, WJ | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
2 reviews available for bepridil and Auricular Fibrillation
| Article | Year |
|---|---|
[Best strategy for the treatment of atrial fibrillation: reconsideration after randomized multicenter clinical trials in Japan].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electric Countershock; Evidence-Based Medicin | 2010 |
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
19 trials available for bepridil and Auricular Fibrillation
| Article | Year |
|---|---|
Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Area Under Curve; Asian People; Atrial Fibrillation; Bepr | 2013 |
Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dose-Response Relationship, Drug; Doubl | 2009 |
Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cross-Over Studies; Electrocardiography | 2009 |
Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biomarkers; Biphenyl Co | 2010 |
Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Follow-Up | 2010 |
The relationship between the plasma concentration of bepridil and its efficacy in the treatment of atrial fibrillation in Japanese patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2012 |
Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dose-Response Relationship, Drug; | 2012 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Car | 2013 |
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol | 2002 |
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Flecainide; Huma | 2003 |
Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.
Topics: Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Heart | 2003 |
Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Atrial Function; Bepridil; Disease-Free Surv | 2004 |
Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Bepridil; Drug Therapy, Combination; E | 2004 |
Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
Topics: Action Potentials; Aged; Atrial Fibrillation; Bepridil; Carbazoles; Carvedilol; Electric Countershoc | 2005 |
Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bepridil; Bradycardi | 2006 |
Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Bepridil; Drug Combinations; Drug Resistance | 2006 |
Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Drug Therapy, Combination; Electrocardi | 2007 |
Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Bepridil; C-Reactive Protein; Drug The | 2007 |
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Bepridil; Drug | 2008 |
30 other studies available for bepridil and Auricular Fibrillation
| Article | Year |
|---|---|
The potential effect of bepridil on vasospastic angina in atrial fibrillation patients undergoing catheter ablation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Catheter Ablation; Coronary Vasospasm; Humans | 2023 |
Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Atrial Fibrillation; | 2023 |
Efficacy of hybrid therapy using prior administration of bepridil hydrochloride and cryoballoon ablation in patients with persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Bepridil; Catheter Ablation; C | 2020 |
Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Catheter Ablation; Dose-Response Rela | 2021 |
Correlation between inflammation state and successful medical cardioversion using bepridil for refractory atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Biomarkers; C-Reactive Protein; Electri | 2013 |
Bepridil enhances aprindine-induced prolongation of atrial effective refractory period in a canine atrial rapid pacing model.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Atrial Function; Atrial Remodeling; | 2015 |
Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies; Catheter Ab | 2016 |
Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Bepri | 2016 |
Two patients with bepridil-induced interstitial pneumonia.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Diagnosis, Differential; Heart Failure; | 2009 |
Does bepridil create a paradigm shift in the treatment of persistent atrial fibrillation?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dose-Response Relationship, Drug; Electrocard | 2009 |
Opposing effects of bepridil on ventricular repolarization in humans. Inhomogeneous prolongation of the action potential duration vs flattening of its restitution kinetics.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies | 2009 |
Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Catheter Ablation; Chronic Disease; Electroca | 2009 |
Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. - Prevention of vagal nerve activation-induced shortening of the atrial action potential duration -.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dogs; Heart Rate; | 2010 |
Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepri | 2012 |
Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cardiovascular Diseases; Dose-Response | 2011 |
An LC method for quantifying bepridil in human plasma using 1-naphthol as the internal standard.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Chromatography, High Pressure Liquid; Humans; | 2011 |
[Series: Clinical study from Japan and its reflections; J-BAF study].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Clinical Trials as Topic; Humans | 2011 |
Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Dose-Response Relationship, Drug; Dru | 2011 |
Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Drug Resistance, Mul | 2012 |
Pharmacological conversion of atrial fibrillation in the patients of Graves' disease.
Topics: Administration, Oral; Adult; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Female; Graves | 2012 |
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Electrocardio | 2003 |
A case of bepridil induced interstitial pneumonitis.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Humans; Lung Diseases, Interstitial; Ma | 2003 |
Atrial fibrillatory frequency, atrial fibrillatory rate, or atrial cycle length--does it matter?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Confounding Factors, Epidemiologic; Heart Rat | 2004 |
Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardio | 2005 |
Fibrillation cycle length and fibrillatory rate obtained from peak frequency of fibrillation waves.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Endpoint Determination; Humans; Reproducibili | 2005 |
[A case of drug-induced pneumonitis due to bepridil].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Humans; Male; Pneumonia | 2006 |
[Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cardiomy | 2006 |
Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Ag | 2007 |
Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model.
Topics: Animals; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Calcium Channels; Cardiac Pacing, | 2008 |
A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bepridil; Chron | 1987 |